Medicamen Biotech Limited — Important, 25-10-2024: General Updates

Medicamen Biotech Limited announced that the US FDA has approved its sterile injectable oncology formulation facility in Haridwar, specifically for the Bortezomib for Injection 3.5 mg/vial product. The approval comes following an inspection conducted on April 26, 2024, with the Establishment Inspection Report (EIR) now issued.